Should a patient with mood disorder, including schizophrenia and bipolar disorder, be started on Invega (paliperidone) long‑acting injectable, and what dosing and monitoring are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Invega (Paliperidone) for Mood Disorders: Schizophrenia, Schizoaffective, and Bipolar Disorder

Yes, Invega (paliperidone) long-acting injectable is appropriate for patients with schizophrenia and schizoaffective disorder, and the FDA-approved dosing is 150 mg equivalent on day 1 followed by 100 mg equivalent on day 8 (both deltoid injections), then 75 mg equivalent monthly maintenance doses. However, Invega is NOT FDA-approved for bipolar disorder as monotherapy 1.

FDA-Approved Indications

Invega (paliperidone palmitate) long-acting injectable is FDA-approved for:

  • Schizophrenia: Acute and maintenance treatment 1
  • Schizoaffective disorder: As monotherapy OR as adjunct to mood stabilizers/antidepressants 1

Critical caveat: Invega is NOT approved for bipolar disorder alone. If your patient has bipolar disorder without psychotic features, this is off-label use 1.

Dosing Protocol (FDA-Approved)

Initiation Regimen

  • Day 1: 150 mg eq. paliperidone (234 mg paliperidone palmitate) deltoid injection
  • Day 8 (±2 days): 100 mg eq. paliperidone (156 mg paliperidone palmitate) deltoid injection
  • No oral supplementation required 1, 2, 3

Needle selection for initiation:

  • Weight <90 kg: 1-inch, 23-gauge needle
  • Weight ≥90 kg: 1.5-inch, 22-gauge needle 1, 3

Maintenance Dosing

  • Recommended dose: 75 mg eq. paliperidone (117 mg) monthly
  • Dose range: 25-150 mg eq. (39-234 mg) based on response
  • Timing flexibility: ±7 days from scheduled monthly dose 1
  • Injection site: Deltoid (weight-adjusted needle) OR gluteal (1.5-inch, 22-gauge) 1

Dose Adjustments

Increase doses by 3 mg increments only after clinical reassessment, with intervals >4-5 days between increases 1.

Special Populations

Renal Impairment (Critical)

  • Mild impairment (CrCl 50-80 mL/min): Start 3 mg daily oral (if using tablets), max 6 mg; adjust LAI accordingly
  • Moderate-severe (CrCl 10-50 mL/min): Start 1.5 mg daily oral, max 3 mg 1
  • CrCl <10 mL/min: Not recommended 1

Hepatic Impairment

  • Mild-moderate (Child-Pugh A/B): No adjustment needed
  • Severe: Not studied, use with caution 1

Elderly

  • Same dosing as younger adults IF renal function normal
  • Adjust for age-related decline in creatinine clearance 1

Clinical Evidence Supporting Use

Schizoaffective Disorder

The APA guidelines recommend long-acting injectables for patients with poor adherence history 4. Paliperidone palmitate significantly delayed relapse of psychotic, depressive, AND manic symptoms in schizoaffective disorder (hazard ratio 2.49 for placebo vs. paliperidone, p<0.001) 5. Relapse rates were 15.2% for paliperidone vs. 33.5% for placebo, with benefits seen both as monotherapy and adjunctive therapy 5.

Schizophrenia

Long-term effectiveness data shows sustained reduction in hospitalizations and emergency visits for up to 10 years after initiating paliperidone palmitate 6. The APA strongly recommends (1A) that patients with schizophrenia be treated with antipsychotics and suggests (2B) LAIs for those with adherence problems 4.

Bipolar Disorder (Off-Label)

Important limitation: While some evidence suggests LAIs prevent manic episodes in bipolar disorder, paliperidone palmitate lacks FDA approval for bipolar disorder without psychotic features 7, 8. A 2019 systematic review found LAIs more effective for preventing mania than depression in bipolar disorder 7. Use in adolescents with bipolar mania showed YMRS score improvements from 33.8 at baseline to 3.0 at 1 year, but this remains off-label 8.

Switching Strategies

From Oral Antipsychotics

  • Initiate paliperidone palmitate the day after discontinuing oral medication 2, 3
  • No oral overlap needed with the loading dose regimen 2

From Other LAIs

  • Start paliperidone palmitate at the time of the next scheduled injection of the previous LAI 2, 3
  • Continue monthly thereafter

Avoiding Risperidone Overlap

Do not combine with risperidone (oral or LAI), as paliperidone is risperidone's active metabolite—this creates additive exposure risk 1

Monitoring Requirements

The APA recommends monitoring for:

  • Effectiveness: Symptom severity using quantitative measures 4
  • Side effects: Metabolic parameters, extrapyramidal symptoms, tardive dyskinesia 4
  • Renal function: Especially in elderly patients 1

Common adverse events: Weight gain (8.5%), insomnia (4.9%), headache (5.5%), extrapyramidal symptoms (8.5%) 5

Critical Warnings

Black Box Warning

Elderly patients with dementia-related psychosis have 1.6-1.7 times increased mortality risk with antipsychotics (4.5% vs. 2.6% on placebo over 10 weeks), primarily from cardiovascular or infectious causes 1. Invega is NOT approved for dementia-related psychosis 1.

Practical Algorithm

  1. Confirm diagnosis: Schizophrenia or schizoaffective disorder (FDA-approved) vs. bipolar disorder (off-label)
  2. Check renal function: Adjust dosing if CrCl <80 mL/min
  3. Initiate loading doses: Day 1 and Day 8 deltoid injections (no oral supplementation)
  4. Begin monthly maintenance: Starting Day 36 (±7 days), dose 75 mg eq. paliperidone
  5. Titrate cautiously: Only increase by 3 mg increments after >4 days if inadequate response
  6. Monitor adherence: Monthly injection schedule improves outcomes vs. oral medications 4, 6

The evidence strongly supports paliperidone palmitate LAI for schizophrenia and schizoaffective disorder, with robust data showing reduced relapse rates and hospitalizations, but use in bipolar disorder without psychotic features remains off-label and should be approached cautiously 4, 1, 5, 6.

Related Questions

How should Invega LAI (paliperidone palmitate) be administered?
After a patient receives Invega Sustenna (paliperidone palmitate), how soon should oral risperidone (Risperdal) be stopped?
Can I administer Invega (paliperidone palmitate) long‑acting injectable to a patient who is only taking risperidone tablets?
If a patient is receiving a delayed 156 mg Invega (paliperidone palmitate) injection, should they continue oral risperidone for a week?
Is it safe to give Invega (paliperidone palmitate) intramuscularly after a patient has received only a single dose of Abilify (aripiprazole) intramuscularly?
Did the West Nile virus outbreak in Greece start in [LOCATION] in 2010, initially affect mainly rural populations, spread widely across mainland Greece, and cause several cases in horses?
Is schizophrenia considered a mood disorder?
What is the appropriate prophylaxis for a 47‑year‑old man with recurrent furunculosis of the scrotum, gluteal/perianal, and groin areas who is currently receiving ceftriaxone 2 g IV daily and has never used a decolonization strategy?
How can a non‑diabetic individual prevent nocturnal hypoglycemia between 2 am and 3 am?
What is the preferred opioid for pain control in an adult hospice patient with end-stage liver failure?
I am taking Armour Thyroid 120 mg daily; my labs show TSH 2.47 µIU/mL (reference 0.4–4.1), total T3 76 ng/dL (reference 80–200), and free T4 0.86 ng/dL (reference 0.8–1.9). How should I manage my thyroid medication?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.